{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T22:09:28Z","timestamp":1785190168605,"version":"3.55.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Egypt Heart J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Amyloidosis is a heterogeneous group of disorders caused by the extracellular deposition of insoluble misfolded proteins, leading to end-organ damage. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a subtype in which a protein known as transthyretin accumulates within the heart tissue, progressively resulting in restrictive cardiomyopathy and heart failure. Due to the progressive nature of ATTR-CM, clinical management requires efficacious regimens to manage the debilitating condition and Tafamidis shows promising results in this regard.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Main body<\/jats:title>\n                <jats:p>ATTR-CM poses a significant challenge due to its nature and limited therapeutic options. Tafamidis is a novel therapy designed to stabilize the transthyretin tetramers, inhibiting the formation of amyloid fibrils. It has emerged as a promising treatment and the only FDA-approved drug for ATTR-CM. Tafamidis' role in slowing disease progression and improving outcomes in patients with ATTR-CM has been demonstrated in the major randomized control trial ATTR-ACT with promising open-label extension studies, some still ongoing. Additionally, real-world evidence supports its use in clinical practice, showing its role in reducing morbidity and mortality associated with this condition. Clinical evidence shows its efficacy in improving symptoms and cardiac function in patients. Case studies also reveal significant benefits to patients like reducing myocardial damage, reversal of atrial fibrillation, and resolution of heart failure symptoms. Real-world outcomes and clinical trials show a consistent reduction in amyloid deposition, cardiovascular-related hospitalizations, and all-cause mortality with Tafamidis therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Tafamidis is an essential component of the treatment of ATTR-CM and this narrative review synthesizes the current evidence regarding safety, efficacy, and utilization in real practice. While it shows promising effects, its effectiveness may also vary and high cost precludes real-world large-scale studies. Overall, Tafamidis emerges as a valuable therapeutic option for managing ATTR-CM.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s43044-024-00517-y","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T12:02:17Z","timestamp":1720612937000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Tafamidis therapy in transthyretin amyloid cardiomyopathy: a narrative review from clinical trials and real-world evidence"],"prefix":"10.1186","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9465-0089","authenticated-orcid":false,"given":"Ikponmwosa Jude","family":"Ogieuhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oshomoh Mark-Anthony","family":"Ugiomoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kudzaishe","family":"Muzofa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Callender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnson David","family":"Ayodeji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nnokam Prayer","family":"Nnekachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barkavi","family":"Thiyagarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel Obokhai","family":"Uduigwome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhay","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moses Chukwuebuka","family":"Odoeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem Gamaleldin Hassan","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courage","family":"Idahor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,10]]},"reference":[{"key":"517_CR1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s12471-019-1299-1","volume":"27","author":"MI Oerlemans","year":"2019","unstructured":"Oerlemans MI, Rutten KH, Minnema MC, Raymakers RA, Asselbergs FW, de Jonge N (2019) Cardiac amyloidosis: the need for early diagnosis. Neth Heart J 27:525\u2013536","journal-title":"Neth Heart J"},{"key":"517_CR2","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.2147\/DDDT.S289772","volume":"18","author":"A Burton","year":"2021","unstructured":"Burton A, Casta\u00f1o A, Bruno M, Riley S, Schumacher J, Sultan MB, See Tai S, Judge DP, Patel JK, Kelly JW (2021) Drug discovery and development in rare diseases: taking a closer look at the tafamidis story. Drug Des Dev Ther 18:1225\u20131243","journal-title":"Drug Des Dev Ther"},{"issue":"10","key":"517_CR3","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","volume":"126","author":"FL Ruberg","year":"2012","unstructured":"Ruberg FL, Berk JL (2012) Transthyretin (TTR) cardiac amyloidosis. Circulation 126(10):1286\u20131300","journal-title":"Circulation"},{"issue":"5","key":"517_CR4","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/1060028019888489","volume":"54","author":"J Park","year":"2020","unstructured":"Park J, Egolum U, Parker S, Andrews E, Ombengi D, Ling H (2020) Tafamidis: a first-in-class transthyretin stabilizer for transthyretin amyloid cardiomyopathy. Ann Pharmacother 54(5):470\u2013477","journal-title":"Ann Pharmacother"},{"issue":"11","key":"517_CR5","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379(11):1007\u20131016","journal-title":"N Engl J Med"},{"issue":"16","key":"517_CR6","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, Burazor I, Caforio AL, Damy T, Eriksson U, Fontana M (2021) Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 42(16):1554\u20131568","journal-title":"Eur Heart J"},{"issue":"38","key":"517_CR7","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","volume":"36","author":"E Gonz\u00e1lez-L\u00f3pez","year":"2015","unstructured":"Gonz\u00e1lez-L\u00f3pez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P (2015) Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 36(38):2585\u20132594","journal-title":"Eur Heart J"},{"issue":"24","key":"517_CR8","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ (2016) Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133(24):2404\u20132412","journal-title":"Circulation"},{"issue":"6","key":"517_CR9","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jcmg.2016.06.003","volume":"10","author":"M Haq","year":"2017","unstructured":"Haq M, Pawar S, Berk JL, Miller EJ, Ruberg FL (2017) Can 99mTc-pyrophosphate aid in early detection of cardiac involvement in asymptomatic variant TTR amyloidosis? JACC Cardiovasc Imaging 10(6):713\u2013714","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"517_CR10","first-page":"115","volume":"9","author":"C Rapezzi","year":"2021","unstructured":"Rapezzi C, Elliott P, Damy T, Nativi-Nicolau J, Berk JL, Velazquez EJ, Boman K, Gundapaneni B, Patterson TA, Schwartz JH, Sultan MB (2021) Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy: further analyses from ATTR-ACT. Heart Fail 9(2):115\u2013123","journal-title":"Heart Fail"},{"issue":"2","key":"517_CR11","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/ejhf.2027","volume":"23","author":"T Damy","year":"2021","unstructured":"Damy T, Garcia-Pavia P, Hanna M, Judge DP, Merlini G, Gundapaneni B, Patterson TA, Riley S, Schwartz JH, Sultan MB, Witteles R (2021) Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail 23(2):277\u2013285","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"517_CR12","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","volume":"79","author":"T Coelho","year":"2012","unstructured":"Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Plant\u00e9-Bordeneuve V, Lozeron P, Suhr OB, Campistol JM, Concei\u00e7\u00e3o IM, Schmidt HH, Trigo P (2012) Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 79(8):785\u2013792","journal-title":"Neurology"},{"issue":"Supplement_2","key":"517_CR13","doi-asserted-by":"publisher","first-page":"ehac544","DOI":"10.1093\/eurheartj\/ehac544.956","volume":"43","author":"AT Moody","year":"2022","unstructured":"Moody AT, Tess DA, Li Z, Bulawa C, Fleming J, Maurer TS (2022) Relationship of tafamidis binding site occupancy, transthyretin stabilization, and disease modification in tafamidis treated transthyretin amyloid cardiomyopathy patients. Eur Heart J 43(Supplement_2):ehac544-956","journal-title":"Eur Heart J"},{"issue":"24","key":"517_CR14","doi-asserted-by":"publisher","first-page":"9629","DOI":"10.1073\/pnas.1121005109","volume":"109","author":"CE Bulawa","year":"2012","unstructured":"Bulawa CE, Connelly S, DeVit M, Wang L, Weigel C, Fleming JA, Packman J, Powers ET, Wiseman RL, Foss TR, Wilson IA (2012) Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci 109(24):9629\u20139634","journal-title":"Proc Natl Acad Sci"},{"issue":"148","key":"517_CR15","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.amjcard.2021.02.035","volume":"1","author":"AB Miller","year":"2021","unstructured":"Miller AB, Januzzi JL, O\u2019Neill BJ, Gundapaneni B, Patterson TA, Sultan MB, L\u00f3pez-Send\u00f3n J (2021) Causes of cardiovascular hospitalization and death in patients with transthyretin amyloid cardiomyopathy (from the tafamidis in transthyretin cardiomyopathy clinical trial [ATTR-ACT]). Am J Cardiol 1(148):146\u2013150","journal-title":"Am J Cardiol"},{"issue":"11","key":"517_CR16","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1002\/ejhf.2974","volume":"25","author":"P Elliott","year":"2023","unstructured":"Elliott P, Gundapaneni B, Sultan MB, Ines M, Garcia-Pavia P (2023) Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms. Eur J Heart Fail 25(11):2060\u20132064","journal-title":"Eur J Heart Fail"},{"issue":"Supplement_I","key":"517_CR17","doi-asserted-by":"publisher","first-page":"I131","DOI":"10.1093\/eurheartjsupp\/suac104","volume":"24","author":"A Cantone","year":"2022","unstructured":"Cantone A, Sanguettoli F, Dal Passo B, Serenelli M, Rapezzi C (2022) The treatment of amyloidosis is being refined. Eur Heart J Suppl 24(Supplement_I):I131\u2013I138","journal-title":"Eur Heart J Suppl"},{"issue":"1","key":"517_CR18","doi-asserted-by":"publisher","first-page":"e008193","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","volume":"15","author":"P Elliott","year":"2022","unstructured":"Elliott P, Drachman BM, Gottlieb SS, Hoffman JE, Hummel SL, Lenihan DJ, Ebede B, Gundapaneni B, Li B, Sultan MB, Shah SJ (2022) Long-term survival with Tafamidis in patients with transthyretin amyloid cardiomyopathy. Circ Heart Fail 15(1):e008193","journal-title":"Circ Heart Fail"},{"issue":"5","key":"517_CR19","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/ehjqcco\/qcab031","volume":"8","author":"MH Rozenbaum","year":"2022","unstructured":"Rozenbaum MH, Garcia A, Grima D, Tran D, Bhambri R, Stewart M, Li B, Heeg B, Postma M, Masri A (2022) Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies. Eur Heart J Qual Care Clin Outcomes 8(5):529\u2013538","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"517_CR20","first-page":"63","volume":"1","author":"J Wang","year":"2023","unstructured":"Wang J, Chen H, Tang Z, Zhang J, Xu Y, Wan K, Hussain K, Gkoutos GV, Han Y, Chen Y (2023) Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis. EClinicalMedicine 1:63","journal-title":"EClinicalMedicine"},{"issue":"1","key":"517_CR21","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/13506129.2023.2263620","volume":"31","author":"A Wardhere","year":"2024","unstructured":"Wardhere A, Bampatsias D, Fine N, Garcia-Pavia P, Grogan M, Kristen AV, Damy T, Sekijima Y, Maurer MS (2024) Heterogeneous worldwide access and pricing of Tafamidis. Amyloid 31(1):73\u201375","journal-title":"Amyloid"},{"issue":"9","key":"517_CR22","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1002\/ejhf.2589","volume":"24","author":"AS Antonopoulos","year":"2022","unstructured":"Antonopoulos AS, Panagiotopoulos I, Kouroutzoglou A, Koutsis G, Toskas P, Lazaros G, Toutouzas K, Tousoulis D, Tsioufis K, Vlachopoulos C (2022) Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis. Eur J Heart Fail 24(9):1677\u20131696","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"517_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/jamacardio.2023.4147","volume":"9","author":"SJ Shah","year":"2024","unstructured":"Shah SJ, Fine N, Garcia-Pavia P, Klein AL, Fernandes F, Weissman NJ, Maurer MS, Boman K, Gundapaneni B, Sultan MB, Elliott P (2024) Effect of tafamidis on cardiac function in patients with transthyretin amyloid cardiomyopathy: a post hoc analysis of the ATTR-ACT randomized clinical trial. JAMA Cardiol 9(1):25\u201334","journal-title":"JAMA Cardiol"},{"issue":"141","key":"517_CR24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.amjcard.2020.10.066","volume":"15","author":"M Hanna","year":"2021","unstructured":"Hanna M, Damy T, Grogan M, Stewart M, Gundapaneni B, Patterson TA, Schwartz JH, Sultan MB, Maurer MS (2021) Impact of tafamidis on health-related quality of life in patients with transthyretin amyloid cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). Am J Cardiol 15(141):98\u2013105","journal-title":"Am J Cardiol"},{"issue":"1","key":"517_CR25","first-page":"150","volume":"12","author":"P Garcia-Pavia","year":"2024","unstructured":"Garcia-Pavia P, Sultan MB, Gundapaneni B, Sekijima Y, Perfetto F, Hanna M, Witteles R (2024) Tafamidis efficacy among octogenarian patients in the phase 3 ATTR-ACT and ongoing long-term extension study. Heart Fail 12(1):150\u2013160","journal-title":"Heart Fail"},{"issue":"3","key":"517_CR26","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jamacardio.2022.5251","volume":"8","author":"BW Sperry","year":"2023","unstructured":"Sperry BW, Hanna M, Maurer MS, Nativi-Nicolau J, Floden L, Stewart M, Wyrwich KW, Barsdorf AI, Kapadia H, Spertus JA (2023) Association of tafamidis with health status in patients with ATTR cardiac amyloidosis: a post hoc analysis of the ATTR-ACT randomized clinical trial. JAMA Cardiol 8(3):275\u2013280","journal-title":"JAMA Cardiol"},{"issue":"2","key":"517_CR27","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, Grogan M, Hanna M, Hoffman J, Masri A, Maurer MS (2024) Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med 390(2):132\u2013142","journal-title":"N Engl J Med"},{"issue":"2","key":"517_CR28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3109\/13506129.2014.997872","volume":"22","author":"Y Sekijima","year":"2015","unstructured":"Sekijima Y, Tojo K, Morita H, Koyama J, Ikeda SI (2015) Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis. Amyloid 22(2):79\u201383","journal-title":"Amyloid"},{"issue":"6","key":"517_CR29","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1751-7133.2012.00303.x","volume":"18","author":"A Casta\u00f1o","year":"2012","unstructured":"Casta\u00f1o A, Helmke S, Alvarez J, Delisle S, Maurer MS (2012) Diflunisal for ATTR cardiac amyloidosis. Congest Heart Fail 18(6):315\u2013319","journal-title":"Congest Heart Fail"},{"issue":"9","key":"517_CR30","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.cardfail.2019.11.024","volume":"26","author":"G Lohrmann","year":"2020","unstructured":"Lohrmann G, Pipilas A, Mussinelli R, Gopal DM, Berk JL, Connors LH, Vellanki N, Hellawell J, Siddiqi OK, Fox J, Maurer MS (2020) Stabilization of cardiac function with diflunisal in transthyretin (ATTR) cardiac amyloidosis. J Cardiac Fail 26(9):753\u2013759","journal-title":"J Cardiac Fail"},{"key":"517_CR31","doi-asserted-by":"publisher","first-page":"10787","DOI":"10.1038\/ncomms10787","volume":"7","author":"R Sant'Anna","year":"2016","unstructured":"Sant\u2019Anna R, Gallego P, Robinson LZ et al (2016) Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nat Commun 7:10787","journal-title":"Nat Commun"},{"issue":"1","key":"517_CR32","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41598-017-00338-x","volume":"7","author":"G Verona","year":"2017","unstructured":"Verona G, Mangione PP, Raimondi S, Giorgetti S, Faravelli G, Porcari R, Corazza A, Gillmore JD, Hawkins PN, Pepys MB, Taylor GW (2017) Inhibition of the mechano-enzymatic amyloidogenesis of transthyretin: role of ligand affinity, binding cooperativity and occupancy of the inner channel. Sci Rep 7(1):182","journal-title":"Sci Rep"},{"issue":"11S","key":"517_CR33","doi-asserted-by":"publisher","first-page":"A658","DOI":"10.1016\/S0735-1097(18)31199-9","volume":"71","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Heitner S, Drachman B, Whelan C, Guthrie S, Tai L, Hughes SG, Monia BP, Ackermann EJ, Benson MD (2018) Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO-TTR. J Am Coll Cardiol 71(11S):A658","journal-title":"J Am Coll Cardiol"},{"issue":"9S1","key":"517_CR34","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/S0735-1097(19)31516-5","volume":"73","author":"NR Dasgupta","year":"2019","unstructured":"Dasgupta NR, Falk RH, Drachman BM, Maurer MS, Whelan CJ, Brannagan T, Coelho T, Cruz MW, Damy T, Hanna M, Berk JL (2019) Safety of inotersen treatment in patients with transthyretin amyloid cardiomyopathy. J Am Coll Cardiol 73(9S1):909","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"517_CR35","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Plant\u00e9-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379(1):22\u201331","journal-title":"N Engl J Med"},{"key":"517_CR36","unstructured":"Alnylam Pharmaceuticals Inc. US prescribing information: ONPATTRO (patisiran) lipid complex injection, for intravenous use"},{"issue":"17","key":"517_CR37","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","volume":"389","author":"MS Maurer","year":"2023","unstructured":"Maurer MS, Kale P, Fontana M, Berk JL, Grogan M, Gustafsson F, Hung RR, Gottlieb RL, Damy T, Gonz\u00e1lez-Duarte A, Sarswat N (2023) Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med 389(17):1553\u20131565","journal-title":"N Engl J Med"},{"issue":"1","key":"517_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379(1):11\u201321","journal-title":"N Engl J Med"},{"issue":"13","key":"517_CR39","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s40265-022-01765-5","volume":"82","author":"SJ Keam","year":"2022","unstructured":"Keam SJ (2022) Vutrisiran: first approval. Drugs 82(13):1419\u20131425","journal-title":"Drugs"},{"issue":"1","key":"517_CR40","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/13506129.2022.2091985","volume":"30","author":"D Adams","year":"2023","unstructured":"Adams D, Tournev IL, Taylor MS, Coelho T, Plant\u00e9-Bordeneuve V, Berk JL, Gonz\u00e1lez-Duarte A, Gillmore JD, Low SC, Sekijima Y, Obici L (2023) Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid 30(1):18\u201326","journal-title":"Amyloid"},{"key":"517_CR41","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10557-019-06919-4","volume":"34","author":"DP Judge","year":"2020","unstructured":"Judge DP, Kristen AV, Grogan M, Maurer MS, Falk RH, Hanna M, Gillmore J, Garg P, Vaishnaw AK, Harrop J, Powell C (2020) Phase 3 multicenter study of revusiran in patients with hereditary transthyretin-mediated (hATTR) amyloidosis with cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther 34:357\u2013370","journal-title":"Cardiovasc Drugs Ther"},{"issue":"22","key":"517_CR42","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS (2019) Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 73(22):2872\u20132891","journal-title":"J Am Coll Cardiol"},{"issue":"18_Supplement_1","key":"517_CR43","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1016\/S0735-1097(21)04650-7","volume":"77","author":"A Gilad","year":"2021","unstructured":"Gilad A, Joshi T, Mendelson L, Berk J, Sanchorawala V, Ruberg F, Siddiqi O, Gopal D (2021) Treating transthyretin amyloid cardiomyopathy: a comparison of diflunisal and tafamidis. J Am Coll Cardiol 77(18_Supplement_1):3296","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"517_CR44","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1253\/circj.CJ-22-0683","volume":"87","author":"Y Ichikawa","year":"2023","unstructured":"Ichikawa Y, Oota E, Odajima S, Kintsu M, Todo S, Takeuchi K, Yamauchi Y, Shiraki H, Yamashita K, Fukuda T, Hisamatsu E (2023) Impact of tafamidis on echocardiographic cardiac function of patients with transthyretin cardiac amyloidosis. Circ J 87(4):508\u2013516","journal-title":"Circ J"},{"issue":"8","key":"517_CR45","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1093\/ehjci\/jeac049","volume":"23","author":"GT Giblin","year":"2022","unstructured":"Giblin GT, Cuddy SA, Gonz\u00e1lez-L\u00f3pez E, Sewell A, Murphy A, Dorbala S, Falk RH (2022) Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis. Eur Heart J Cardiovasc Imaging 23(8):1029\u20131039","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"6","key":"517_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.101667","volume":"48","author":"A Ghoneem","year":"2023","unstructured":"Ghoneem A, Bhatti AW, Khadke S, Mitchell J, Liu J, Zhang K, Trachtenberg B, Wechalekar A, Cheng RK, Baron SJ, Nohria A (2023) Real-world efficacy of tafamidis in patients with transthyretin amyloidosis and heart failure. Curr Probl Cardiol 48(6):101667","journal-title":"Curr Probl Cardiol"},{"issue":"12","key":"517_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101358","volume":"47","author":"K Hussain","year":"2022","unstructured":"Hussain K, Macrinici V, Wathen L, Balasubramanian SS, Minga I, Gaznabi S, Kwak E, Wang CH, Iqbal SH, Pursnani A, Sarswat N (2022) Impact of tafamidis on survival in a real-world community-based cohort. Curr Probl Cardiol 47(12):101358","journal-title":"Curr Probl Cardiol"},{"issue":"2","key":"517_CR48","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/ejhf.2028","volume":"23","author":"M B\u00e9zard","year":"2021","unstructured":"B\u00e9zard M, Kharoubi M, Galat A, Poullot E, Guendouz S, Fanen P, Funalot B, Moktefi A, Lefaucheur JP, Abulizi M, Deux JF (2021) Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis. Eur J Heart Fail 23(2):264\u2013274","journal-title":"Eur J Heart Fail"},{"issue":"9_Supplement","key":"517_CR49","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S0735-1097(22)01297-9","volume":"79","author":"S Amaka","year":"2022","unstructured":"Amaka S, Bhattacharya PT, Maurer MS, Griffin J (2022) Tafamidis effectiveness in wild-type transthyretin cardiac amyloidosis by Mayo staging. J Am Coll Cardiol 79(9_Supplement):306","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"517_CR50","doi-asserted-by":"publisher","first-page":"omac007","DOI":"10.1093\/omcr\/omac007","volume":"2022","author":"Y Isotani","year":"2022","unstructured":"Isotani Y, Amiya E, Ishida J, Ishizuka M, Hatano M, Nakanishi K, Daimon M, Komuro I (2022) Recovery of sinus rhythm by tafamidis in patients with wild-type transthyretin amyloid cardiomyopathy with atrial arrhythmias. Oxf Med Case Rep 2022(2):omac007","journal-title":"Oxf Med Case Rep"},{"key":"517_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2024.03.007","author":"R Witteles","year":"2024","unstructured":"Witteles R, Jefferies JL, Kapa S, Cappelli F, Sultan MB, Gundapaneni B et al (2024) Atrial fibrillation as a prognostic factor for all-cause mortality in patients with transthyretin amyloid cardiomyopathy. JACC: CardioOncology. https:\/\/doi.org\/10.1016\/j.jaccao.2024.03.007","journal-title":"JACC: CardioOncology."},{"issue":"1","key":"517_CR52","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/MS9.0000000000001482","volume":"86","author":"M Sukaina","year":"2024","unstructured":"Sukaina M, Rehman S, Waheed M, Shehryar M, Rasool R, Ahmed N, Ochani S, Al HM (2024) Efficacy of tafamidis in transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis. Ann Med Surg 86(1):433\u2013438","journal-title":"Ann Med Surg"},{"issue":"7","key":"517_CR53","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1253\/circj.CJ-21-0965","volume":"86","author":"Y Ochi","year":"2022","unstructured":"Ochi Y, Kubo T, Baba Y, Sugiura K, Miyagawa K, Noguchi T, Hirota T, Hamada T, Yamasaki N, Kitaoka H (2022) Early experience of tafamidis treatment in Japanese patients with wild-type transthyretin cardiac amyloidosis from the Kochi amyloidosis cohort. Circ J 86(7):1121\u20131128","journal-title":"Circ J"},{"issue":"8","key":"517_CR54","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1253\/circrep.CR-20-0062","volume":"2","author":"M Nakamura","year":"2020","unstructured":"Nakamura M, Imamura T, Hori M, Ushijima R, Joho S, Kinugawa K (2020) Initial experience with tafamidis treatment for transthyretin amyloid cardiomyopathy. Circ Rep 2(8):420\u2013424","journal-title":"Circ Rep"},{"issue":"11","key":"517_CR55","first-page":"e48365","volume":"15","author":"S Chakraborty","year":"2023","unstructured":"Chakraborty S, Golzarian H, Grewal H, Singh H (2023) A case of infiltrative cardiomyopathy with refractory pericardial effusion successfully treated with empiric tafamidis. Cureus 15(11):e48365","journal-title":"Cureus"},{"issue":"6","key":"517_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ehjcr\/ytaa382","volume":"4","author":"A Chiou","year":"2020","unstructured":"Chiou A, Aman E, Kesarwani M (2020) A case report of an infiltrative cardiomyopathy in everyday practice: a specific cause that cannot be missed in the elderly. Eur Heart J Case Rep 4(6):1\u20136. https:\/\/doi.org\/10.1093\/ehjcr\/ytaa382","journal-title":"Eur Heart J Case Rep"},{"issue":"2","key":"517_CR57","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1159\/000455089","volume":"137","author":"T Fujita","year":"2017","unstructured":"Fujita T, Inomata T, Kaida T, Iida Y, Ikeda Y, Nabeta T, Ishii S, Maekawa E, Naruke T, Koitabashi T, Kitamura E (2017) Tafamidis for the treatment of hereditary transthyretin amyloid cardiomyopathy: a case report. Cardiology 137(2):74\u201377","journal-title":"Cardiology"},{"issue":"3.4","key":"517_CR58","doi-asserted-by":"publisher","first-page":"320","DOI":"10.2152\/jmi.69.320","volume":"69","author":"S Yagi","year":"2022","unstructured":"Yagi S, Yamazaki H, Kusunose K, Osaki Y, Ise T, Kadota M, Tserensonom M, Kawabata Y, Hara T, Ueno R, Saijo Y, Matsuura T, Yamaguchi K, Yamada H, Fukuda D, Soeki T, Wakatsuki T, Sata M (2022) Regression of left ventricular hypertrophy after tafamidis therapy in a patient with transthyretin amyloidosis variant. J Med Investig 69(3.4):320\u2013322. https:\/\/doi.org\/10.2152\/jmi.69.320","journal-title":"J Med Investig"},{"key":"517_CR59","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s12265-015-9613-9","volume":"8","author":"T Damy","year":"2015","unstructured":"Damy T, Judge DP, Kristen AV, Berthet K, Li H, Aarts J (2015) Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis. J Cardiovasc Transl Res 8:117\u2013127","journal-title":"J Cardiovasc Transl Res"},{"issue":"2","key":"517_CR60","doi-asserted-by":"publisher","first-page":"73","DOI":"10.14797\/mdcvj.1071","volume":"18","author":"B Trachtenberg","year":"2022","unstructured":"Trachtenberg B (2022) Future directions in cardiac amyloidosis. Methodist Debakey Cardiovasc J 18(2):73","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"9","key":"517_CR61","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.3390\/jcm11092360","volume":"11","author":"RC Rimbas","year":"2022","unstructured":"Rimbas RC, Balinisteanu A, Magda SL, Visoiu SI, Ciobanu AO, Beganu E, Nicula AI, Vinereanu D (2022) New advanced imaging parameters and biomarkers\u2014a step forward in the diagnosis and prognosis of TTR cardiomyopathy. J Clin Med 11(9):2360","journal-title":"J Clin Med"},{"issue":"Supplement_B","key":"517_CR62","doi-asserted-by":"publisher","first-page":"B79","DOI":"10.1093\/eurheartjsupp\/suad079","volume":"25","author":"M Emdin","year":"2023","unstructured":"Emdin M, Morfino P, Crosta L, Aimo A, Vergaro G, Castiglione V (2023) Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis. Eur Heart J Suppl 25(Supplement_B):B79-84","journal-title":"Eur Heart J Suppl"},{"issue":"6","key":"517_CR63","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, Seitzer J, O\u2019Connell D, Walsh KR, Wood K, Phillips J (2021) CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med 385(6):493\u2013502","journal-title":"N Engl J Med"}],"container-title":["The Egyptian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-024-00517-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43044-024-00517-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-024-00517-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T13:04:05Z","timestamp":1720616645000},"score":1,"resource":{"primary":{"URL":"https:\/\/tehj.springeropen.com\/articles\/10.1186\/s43044-024-00517-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,10]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["517"],"URL":"https:\/\/doi.org\/10.1186\/s43044-024-00517-y","relation":{},"ISSN":["2090-911X"],"issn-type":[{"value":"2090-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,10]]},"assertion":[{"value":"8 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}